GSK Investigational Site

Wuhan, Hubei 430060

0 studies enrolling now · 11 studies all time

What they study most

Arthritis, Rheumatoid, Hepatitis B, Hypertension, Lung Cancer, Non-Small Cell, Lupus Nephritis, Neoplasms, Breast, Neoplasms, Head and Neck, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) — Stopped early
• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) — Stopped early
• A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) — Completed
• Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis — Completed
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) — Stopped early
• Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. — Stopped early
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed
• Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery — Completed